SRI scientists collaborate with Lawrence Berkeley National Laboratory to chart a path for obtaining regulatory approval for a clinical development plan for a novel decorporation agent.
Biomedical sciences
HOPO: Partnering to Advance Therapy for Radiation Exposure
The risk of depression in emerging adults suddenly tripled during COVID-19, and young women are particularly vulnerable
SRI’s Dr. Fiona Baker speaks on the results of a recent study on the increased risk of depression during the COVID 19 pandemic.
Techneins™ – Non-natural polymers as synthetic affinity reagents and novel therapeutics
A rapid discovery platform for non-natural polymers that expands our access to 3-dimensional structural diversity with the synthetic accessibility and optimizability of small molecules.
SynFini™
SRI Biosciences has developed SynFini™, a suite of tools that leverages AI to automate the translation of ideas into testable physical molecules.The SynFini platform helps scientists maximize time spent on what to make, rather than how to make by accelerating chemistry design, developme
FOX Three Molecular Guidance System (MGS)™
Cell-selective, intracellular delivery of macromolecular therapeutics
75 Years of Innovation: Twin Research Registry
The Twin Research Registry is a community registry of identical and fraternal twins to help in research into diseases, traits and behaviors
SRI International’s Parijat Bhatnagar receives DARPA award to continue groundbreaking research into engineered immunity
The prestigious award provides additional funds to continue developing cells that can be stimulated via extracorporeal devices to treat viral infections
SRI International Enters Drug Discovery and Research Collaboration with Sanofi
The SRI-Sanofi collaboration will also use SRI’s recently implemented DASL (Deep Adaptive Semantic Logic) tool
SRI International enters drug discovery and research collaboration with Sanofi
Researchers will leverage SynFini, SRI’s artificial intelligence and automation platform, to accelerate development of small-molecule drug targets
Targeted Antigen Loaded Liposomes (TALL)
SRI scientists exploit the human immune response to target cancer cells and extend the benefits of cancer immunotherapies. SRI’s Targeted Antigen Loaded Liposomes (TALL), a new immunotherapy with the potential to overcome these challenges and extend the benefits of immunotherapy to many more patients.
SRI International releases major update to its BioCyc family of websites
SRI International is pleased to announce a major update to the BioCyc family of websites. SRI’s BioCyc solution features a collection of nearly 18,000 Pathway/ Genome Databases (PGDBs) for sequenced bacteria and major eukaryotes and supporting software tools. BioCyc provides a reference on the genomes, metabolic pathways of thousands of sequenced organisms and the regulatory networks of some of the organisms. BioCyc data is obtained by combining computational inferences, import data from other databases, and […]
SRI International receives IARPA contract for rapid, breath-based disease-detection system
SRI International has been awarded a contract under the Intelligence Advanced Research Projects Activity (IARPA) to evaluate whether a novel, prototype technology has the potential to detect COVID-19 and other infectious diseases through exhaled human breath. The rapid, noninvasive technology is designed to provide widespread disease screening in places such as malls, airports, stadiums, emergency […]
Here’s a calendar trick to ease post-pandemic reentry
Wired features SRI Human Sleep Lab’s sleep survey around sleep habits and changes in mood during COVID-19
Advanced manufacturing technologies shift outside the box
PharmTech discusses SRI’s SynFini platform for accelerating chemistry design, development and synthesis
